

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4700060
<b>Application Number:</b>	10524963
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3567
<b>Title of Invention:</b>	N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4'-1,3,4-oxadiazol-2-ylphenyl)pyridine-3- sulphonamide as an anticancer agent
<b>First Named Inventor/Applicant Name:</b>	David William Tonge
<b>Customer Number:</b>	44992
<b>Filer:</b>	Jacob G. Weintraub
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	100815-1P US
<b>Receipt Date:</b>	30-JAN-2009
<b>Filing Date:</b>	18-FEB-2005
<b>Time Stamp:</b>	22:54:02
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (5B/08)	100815IDS1.pdf	1260268 <small>8a9154c16bb6f1b96a321b2d75c7616aa37a899</small>	no	8

### Warnings:

### Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

2	Information Disclosure Statement (IDS) Filed (SB/08)	100815IDS2.pdf	1157877 b171e99b2791a1c1c3b2b73cc3c3b9b9150a4	no	6
---	---	----------------	--	----	---

**Warnings:**

**Information:**

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

3	NPL Documents	01BradburyJMedChem1997996 100440.PDF	1888642 8b15d69b9b93a7f93ca99b415701086f5da095	no	9
---	---------------	---	---	----	---

**Warnings:**

**Information:**

4	NPL Documents	02Brooks2008abstract.PDF	130964 c2acba1271625745510ab8e55726d0036c8bb	no	1
---	---------------	--------------------------	---	----	---

**Warnings:**

**Information:**

5	NPL Documents	03CarducciClinCancerRes20066 296s6300s12.PDF	1173651 c8ade1741bc2ab26958c139ffc570reedaf75a1	no	5
---	---------------	---	--	----	---

**Warnings:**

**Information:**

6	NPL Documents	04CarducciAscoAbstracts2001. PDF	174600 d432c0ef546bdf143a1cd8f2994a7e0271a1b	no	2
---	---------------	-------------------------------------	---	----	---

**Warnings:**

**Information:**

7	NPL Documents	05Carragher2008abstractB77. PDF	99407 a1296dad75d16031892c094c4f70159fcd79b	no	1
---	---------------	------------------------------------	--	----	---

**Warnings:**

**Information:**

8	NPL Documents	06ChiaoBritishJournalofCancer 2000360365833.PDF	972254 01a1e29af0bf464c4debbacc8a21921123dc	no	6
---	---------------	--	--	----	---

**Warnings:**

**Information:**

9	NPL Documents	07ChirgwinJMuscNeuronInteract200430831843.PDF	2214235 a46c20516d80186c2740c774882ae9135471	no	11
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	08ClarksonJonesDrugMetabRev200820640supp3abs283.PDF	160023 d11bd97e8d8d0238c62b2b4e446c1bcb161da	no	1
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	09ClarksonJones2008poster.PDF	310484 2f1bcb55641617b27c46f4d235dc13a1f25d4d6	no	1
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	10CurwenMolCancerTher2007612SupplabsA272.PDF	492314 1185c0d9a0e6d818c28d195c280f70c1c7c0b	no	2
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	11Curwen2007poster.PDF	802283 c0b2de891cc57d815d77a965c6af011a20b1d08	no	1
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	12Curwen2007oralpresentation.PDF	3348300 ccc93e9a681558371a00189778175c09335cda	no	10
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	15Dawson2008oralpresentation.PDF	1897749 e6135726e18f90a2328ba0516e519747a08012d15	no	17
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	16Dawson2008GenitourinaryCancersSympabst7.PDF	81758 a4ef8a6601281ea182d2f04221d5d401721d495c1b	no	1
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	17Dawson2008poster.PDF	482370 a174d2a788a673a5f59d16d5c751bd5fa0261	no	1
<b>Warnings:</b>					
<b>Information:</b>					

18	NPL Documents	18DingemansBrJClinPharmacol200235536253.PDF	1268739 0c1336cb6a618ef12c4821d2c95efeb1b2674c5b	no	8
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	19FizaziAscoAbstracts2001.PDF	137370 fa3d400cc12dc78bfed11ea247181ee911bce8b0	no	1
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	13Curwen2007posteritaly.PDF	1575379 1ebfb3e137d9b075d20081012056c58b1640b6440d	no	1
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	14DawsonCurrentTreatOptionsOncol20081051079suppl1.PDF	118723 cc1e89c2d181fec787c174e5bbcc72a4e059bb	no	4
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	20GodaraUrology2007209215701.PDF	3718148 2e8b0da1d14c95d9c8d0117e5ebee6cd3d8079	no	7
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	21GodaraTheProstate2005273465.PDF	1474743 cd38ba18f0ef1d27d833c3d4d8fc3d8dc33ac5d	no	8
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	22GrossGoupilEuropeanUrologySupp20091141198.PDF	1106014 6d06abc1192e535de6e978dbac35baec3d4e49	no	6
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	23Growcott2008ManchesterPoster.PDF	723436 b0c65b0ed1482726d140ac2bd172da70cc1b5d81	no	1
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	24Growcott2007ItalyPoster.PDF	1017966 cd1647003cc4b494c320338832c59188f1c80c	no	1
<b>Warnings:</b>					
<b>Information:</b>					

27	NPL Documents	25Growcott2007Italyoralpresentation.PDF	553475 094986c3efcd9129b8b463fca387d5d7dc1014	no	3
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	26GrowcottMolCancerTher2007612SupplAbsB269.PDF	254002 3021822af112b771481abdc5efbaff7bc146cd	no	1
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	27Growcott2007ACCRPoster.PDF	324205 536c894d0bc1cc79e98184d6f5619413b29dd40	no	1
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	28GrowcottAnticancerdrugs200900000000.PDF	1097344 5a0bfafcf9e7627575d01026516d2ef69f0147	no	6
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	29GuiseAscoAbstracts2001.PDF	106744 666377eb2eb518311f5cb8361efc64e0825d49	no	1
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	30HickinsonProcAmAssocCancerRes200849abs1487.PDF	139471 d3b17f1e97f5d488169d1300c0a3de499e1820c7	no	2
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	31Hickinson2008poster.PDF	352000 b5146d88e9dd6df4caada7aef792cfb50cc4ed3	no	1
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	32Isherwood2008poster.PDF	669008 6eac622f8bae078a75c5d49f183a3bd45d4c5c3b39	no	1
<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	33James2007absO2.PDF	152939 d627f87e198bd258f0508bb771d31a99f72c5d4d	no	3
<b>Warnings:</b>					
<b>Information:</b>					

36	NPL Documents	34James2008oralpresentation.PDF	1183066 11a8b6c89157ee8f18E28d275c134dc53f46c	no	14
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	35James2007abstractP10.PDF	151055 d53b64a7219c2aba7d6bc18cc3b3acbfce75ee11	no	2
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	36James2007SpainPoster.PDF	307920 98452553e4f58ab111e35e660b1e35202d5e25	no	1
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	37James2007oralpresentation.PDF	3286330 2772ae1854ef6ea6195ef8768c1ee61e1ef2c55	no	19
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	38JamesEurUrol2008.PDF	3637069 d1da2abb1e06dc5d88050437840b100178c3114	no	12
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	39JamesEuropeanJournalofCancerSupp2007abs3LB.PDF	156708 685da99768bc4f9c900284227abs5f0705214b1	no	1
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	40Kenyon2007poster.PDF	823139 3bda713641773c257dc05e4786c82db2c8d7	no	1
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	41KnightProcAmAssocCancerRes200748abs1135.PDF	136819 1d820879928c5cd88d4192bb6e95653dc7804c	no	2
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	42KnightAACR2007Poster.PDF	1220442 6a9d4271521273ed15c8f6f5d8b73d65e33a0	no	1
<b>Warnings:</b>					
<b>Information:</b>					

45	NPL Documents	43KnightIntJJournalofOncology 200946547134.PDF	2357127 3084a7955972da1c5e7973b182950a02af a855	no	7
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	44KopetzInvestNewDrugs2002 17318220options1.pdf	559946 8f93c2a9d1e7c5a8da15c0ff82a1281cc a10a2	no	10
<b>Warnings:</b>					
<b>Information:</b>					
47	NPL Documents	45Mohammad20051213a.PDF	80045 c161b2b78b1905c1a6e9cbe08d51ac1 271d8	no	1
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	46NelsonNeoplasia2005631637 77abstract.PDF	1372734 2200000bc0d1881c0f5d0514d4e1907e 0bae	no	7
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	47NelsonNatureReviewsCancer 20031101163.PDF	1640641 0455a251d6000127d726a18a313a1b0a0e 4c77b	no	7
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	48NelsonAscoAbstracts2001. PDF	116298 a861c5f1546d72b228d453445d483d812 66015	no	1
<b>Warnings:</b>					
<b>Information:</b>					
51	NPL Documents	49Payne2008oralpresentation. PDF	1676065 ec7ab9f409ccc26cda18b6ce2a0d5c8d0 8c20	no	15
<b>Warnings:</b>					
<b>Information:</b>					
52	NPL Documents	50PflugMolCancerTher2007612 SuppllabsA287.PDF	500796 5101b403c86e57413c3018b0ab69dedc25 b8baf	no	2
<b>Warnings:</b>					
<b>Information:</b>					
53	NPL Documents	51RansonEurJCancerSuppl200 711211354abs718.PDF	495789 53c65c6d0f61b186d5f600a2777bea9a20 7ff	no	2
<b>Warnings:</b>					
<b>Information:</b>					

54	NPL Documents	52Ranson2007Poster.PDF	288466 d4e87a8d8ba508538c20702b497A0231d11f696be	no	1
<b>Warnings:</b>					
<b>Information:</b>					
55	NPL Documents	53RosanoEurJCancerSupp2008546Abs168.PDF	260636 c3e61636595a363c9508170b06a65c25d9fa3d2	no	1
<b>Warnings:</b>					
<b>Information:</b>					
56	NPL Documents	54RosanoProcAmAssocCancerRes200849abs2574.PDF	136598 8825c71b40a12020bcdfce9178a3f1ca9f920912e0d	no	2
<b>Warnings:</b>					
<b>Information:</b>					
57	NPL Documents	55Rosano2008presentation.PDF	9440122 bee5d288c6e0dedf11403c238dc119153d5812c	no	16
<b>Warnings:</b>					
<b>Information:</b>					
58	NPL Documents	56RosanoAACR2007abstract5636.PDF	135832 8261aabb728ba691a958ece897afcc0a93d3208b	no	2
<b>Warnings:</b>					
<b>Information:</b>					
59	NPL Documents	57RosanoClinScience20023065309S103supp48.PDF	630312 851f5c93a3fac330ccafad948b9ab62154e94ab5	no	4
<b>Warnings:</b>					
<b>Information:</b>					
60	NPL Documents	58RosanoAAC2008abstractPR15.PDF	107687 9ec8777d3a4d8ab79117905ca12a2762acfe8245	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			62138527		



This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.